# OnCo record idea-pdac-neoadjuvant-chemotherapy-for-all-resectable-disease (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-pdac-neoadjuvant-chemotherapy-for-all-resectable-disease/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-pdac-neoadjuvant-chemotherapy-for-all-resectable-disease" ;
  schema:name "Chemotherapy before surgery for every resectable pancreatic cancer, settled by the two perioperative trials rather than assumed"@en ;
  schema:description "Giving chemotherapy before the operation is standard when the tumour is borderline operable, but for tumours that can be removed straight away two trials have failed to show it beats operating first. Two more, one Dutch and one American, are directly comparing chemotherapy before and after surgery with chemotherapy after alone; the proposal is to wait for them and to pool them."@en ;
  schema:url <https://onco.cc/ideas/idea-pdac-neoadjuvant-chemotherapy-for-all-resectable-disease/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04927780>, <https://clinicaltrials.gov/study/NCT04340141>, <https://europepmc.org/article/MED/40945523> ;
  onco:tag "pancreatic-evidence" ;
  onco:related <https://onco.cc/ideas/idea-ras-inhibitor-neoadjuvant-pdac/>, <https://onco.cc/roadmaps/surgery-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/resectable-pdac/>, <https://onco.cc/cancers/borderline-resectable-pdac/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/folfirinox/> ;
  onco:terms <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/total-neoadjuvant-therapy/>, <https://onco.cc/terms/resectability/>, <https://onco.cc/terms/resection-margins/> ;
  onco:trials <https://onco.cc/trials/preopanc/>, <https://onco.cc/trials/prodige-24/>, <https://onco.cc/trials/espac-5/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-trial-design/>, <https://onco.cc/bottlenecks/b-surgery-radiation-innovation/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-preopanc-preoperative-chemoradiotherapy-jco-2020/>, <https://onco.cc/key-papers/paper-preopanc-2-neoadjuvant-folfirinox-vs-chemoradiotherapy-lancet-oncol-2025/>, <https://onco.cc/key-papers/paper-norpact-1-neoadjuvant-folfirinox-labori-lancet-gastroenterol-hepatol-2024/>, <https://onco.cc/key-papers/paper-prodige-24-five-year-outcomes-jama-oncol-2022/>, <https://onco.cc/key-papers/paper-alliance-a021501-mfolfirinox-radiotherapy-borderline-resectable-jama-oncol-2022/> .